Zydus to sell anti-depressant drug

Drug major Cadila Healthcare Ltd (Zydus Cadila) on Tuesday said it has received final approval from the USFDA to Bupropion Hydrochloride Extended-release tablets USP (XL) in the strength of 300 mg. The drug falls in the anti-depressants segment, according to a company release here. The estimated sales in 2013, as per IMS, for this product were $255.9 million. The total market for Bupropion is estimated at $526.7 million. The group has 87 approvals and has filed 216 ANDAs since the commencement of filing process in FY 2003-04.